^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HS-10502

    i
    Other names: HS-10502
    Associations

    News

    Trials
    Company:
    Jiangsu Hansoh Pharma
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    HS-10502
    1year
    A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=318, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    HS-10502